2019
DOI: 10.1210/js.2019-sat-lb080
|View full text |Cite
|
Sign up to set email alerts
|

SAT-LB080 Peptide Receptor Radionuclide Therapy in Metastatic Pheochromocytoma and Paraganglioma: The Putrajaya Experience

Abstract: BACKGROUND : Most metastatic pheochromocytoma (PCC) and paraganglioma (PGL) express somatostatin receptors (SSTR) similar to neuroendocrine tumors, which may benefit from peptide radionuclide receptor therapy (PRRT), a molecular targeted therapy to SSTR avid tumors. We describe 5 cases of progressive metastatic PCC/PGL who had PRRT from year 2015 to 2018. RESULTS: The patients were aged 18-51 years at diagnosis of PCC/PGL, with mean duration of disease to PRRT of 9.6 (4 - 19) … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance